SGMO

0.6565

5.50% 0.0342

Handel nachbörslich: .63 -0.0265 -4.04%

Sangamo Therapeutics Inc (SGMO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.6223

Offen:

$0.7628

24-Stunden-Volumen:

56.71M

Relative Volume:

8.07

Marktkapitalisierung:

$147.52M

Einnahmen:

$52.29M

Nettoeinkommen (Verlust:

$-134.84M

KGV:

-0.8753

EPS:

-0.75

Netto-Cashflow:

$-117.11M

1W Leistung:

-19.94%

1M Leistung:

-23.64%

6M Leistung:

-15.94%

1J Leistung:

+14.23%

1-Tages-Spanne:

$0.586

$0.7651

1-Wochen-Bereich:

$0.5463

$0.79

52-Wochen-Spanne:

$0.304

$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Firmenname

Sangamo Therapeutics Inc

Sektor

Healthcare (1171)

Branche

Biotechnology (673)

Telefon

(510) 970-6000

Adresse

501 CANAL BLVD., RICHMOND, CA

Mitarbeiter

183

Twitter

@sangamotx

Nächster Verdiensttermin

2025-03-17

Neueste SEC-Einreichungen

SGMO's Discussions on Twitter

Vergleichen Sie SGMO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SGMO Sangamo Therapeutics Inc	0.6565	147.52M	52.29M	-134.84M	-117.11M	-0.75
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-13	Hochstufung	Truist	Hold → Buy
2024-12-10	Bestätigt	H.C. Wainwright	Buy
2023-11-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-04-28	Herabstufung	BofA Securities	Neutral → Underperform
2023-02-27	Hochstufung	Wedbush	Neutral → Outperform
2023-01-06	Herabstufung	BofA Securities	Buy → Neutral
2022-06-13	Fortgesetzt	Wedbush	Neutral
2021-05-04	Eingeleitet	RBC Capital Mkts	Outperform
2021-01-07	Fortgesetzt	Guggenheim	Neutral
2021-01-06	Eingeleitet	Stifel	Hold
2020-12-16	Fortgesetzt	H.C. Wainwright	Buy
2020-09-08	Eingeleitet	BofA Securities	Buy
2020-07-07	Eingeleitet	SunTrust	Buy
2019-08-26	Eingeleitet	H.C. Wainwright	Buy
2018-11-14	Herabstufung	JP Morgan	Overweight → Neutral
2018-11-09	Herabstufung	Guggenheim	Buy → Neutral
2018-10-10	Eingeleitet	Guggenheim	Buy
2018-06-20	Eingeleitet	BofA/Merrill	Buy
2017-11-15	Hochstufung	Piper Jaffray	Neutral → Overweight
2017-06-22	Fortgesetzt	Jefferies	Buy
2016-11-01	Herabstufung	Wedbush	Outperform → Neutral
2016-10-19	Herabstufung	Piper Jaffray	Overweight → Neutral
2015-12-04	Eingeleitet	Wells Fargo	Outperform
2015-10-23	Fortgesetzt	Jefferies	Buy
2013-05-03	Eingeleitet	BioLogic Equity Research	Sell
2011-02-23	Bestätigt	JMP Securities	Mkt Outperform
2010-07-29	Bestätigt	Wedbush	Outperform
2009-10-19	Eingeleitet	Brean Murray	Sell
2009-10-07	Bestätigt	Leerink Swann	Outperform
2009-08-25	Bestätigt	JMP Securities	Mkt Outperform

Alle ansehen

Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten

04:30 AM

Another rebound as Sangamo inks $1.4B capsid deal with Lilly - BioWorld MedTech

04:30 AM

04:23 AM

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com

04:23 AM

02:57 AM

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha

02:57 AM

11:39 AM

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

05:20 AM

Apr 03, 2025

RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga

Apr 03, 2025

Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025

Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada

Apr 03, 2025

Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals

Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener

Apr 03, 2025

Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com India

Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Business Wire

Apr 03, 2025

Apr 02, 2025

5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io

Apr 02, 2025

Mar 31, 2025

Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com

Mar 31, 2025

Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart

Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: - openPR

Mar 20, 2025

Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa

Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India

Mar 19, 2025

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener

Mar 19, 2025

Mar 18, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa

Mar 18, 2025

8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga

Mar 18, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga

Mar 18, 2025

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Mar 18, 2025